Rofecoxib for osteoarthritis (Q24244871)

https://api.crossref.org/works/10.1002%2F14651858.CD005115

A Randomised, Double-Blind, Clinical Trial Comparing the Efficacy of Nimesulide, Celecoxib and Rofecoxib in Osteoarthritis of the Knee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Comparing the efficacy of cyclooxygenase 2–specific inhibitors in treating osteoarthritis: Appropriate trial design considerations and results of a randomized, placebo‐controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Comparative Evaluation of the Effectiveness and Tolerability of Nimesulide Versus Rofecoxib Taken Once a Day in the Treatment of Patients with Knee Osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

The different patterns of blood pressure elevation by rofecoxib and nabumetone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Management pattern for patients with osteoarthritis treated with traditional non-steroidal anti-inflammatory drugs in Spain prior to introduction of Coxibs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

21 January 2018

Cyclooxygenases 1 and 2

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Nonsteroidal anti-inflammatory drugs: effects on kidney function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

7 January 2021

Effects of celecoxib and naproxen on renal function in the elderly

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

7 January 2021

A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

7 January 2021

Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protoco

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

7 January 2021

Baseline risk of gastrointestinal disorders among new users of meloxicam, ibuprofen, diclofenac, naproxen and indomethacin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

7 January 2021

A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

7 January 2021

Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

7 January 2021

Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

7 January 2021

NSAID-induced gastroduodenal damage: is prevention needed? A review and metaanalysis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

7 January 2021

Nonsteroidal antiinflammatory drugs and their effects.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

7 January 2021

COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

7 January 2021

Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005115

7 January 2021